Nutanix downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Sanjit Singh downgraded Nutanix (NTNX) to Equal Weight from Overweight with a price target of $62, down from $82. The firm sees Nutanix as an attractive business having achieved a scale of $2.5B-plus in revenue, but heading into calendar year 2026 it thinks visibility into top-line growth is diminishing. The firm remains optimistic on the longer-run growth opportunity, the analyst added.